cancer research uk cambridge centre early detection ......rebecca is professor of cancer prevention...
TRANSCRIPT
Cancer Research UK Cambridge Centre
Early Detection Programme Annual Symposium
Monday 27th January 2020 CRUK Cambridge Institute
Programme Speaker abstracts and symposium information
Welcome to the CRUK Cambridge Centre
Early Detection Programme Annual Symposium 2020
Please tweet about our symposium using #EDxSymposium2020
PROGRAMME CONTACT DETAILS [email protected] To join our mailing list, please contact us #EDxSymposium2020 @CRUKCamEarlyDx Cancer Research UK Cambridge Centre Early Detection Programme c/o Hutchison-MRC Research Centre PO Box 197 Cambridge Biomedical Campus Cambridge, CB2 0XZ
UPCOMING EARLY DETECTION EVENTS Multidisciplinary Networking event “A novel innate immune checkpoint primes the pre-metastatic niche” by Dr Tim Halim and “Genetic and non-genetic heterogeneity in carcinogenesis” by Dr Alessandro Esposito Monday 24th February 2020 17:30 - 19:00 Seminar Room 1, Clinical School, Cambridge Biomedical Campus (takes place every other month) Early Detection Breakfast meeting “CT screening for lung cancer is coming – but can biomarkers help enrich the populations to screen?” by Dr Robert Rintoul Thursday 12th March 2020 08:30 - 09:30 Jeffrey Cheah Restaurant, Cambridge Biomedical Campus (takes place every other month) A full programme events listing can be found on our website.
11:00
Welcome & Announcement of Pump Priming Award winners Dr Sarah Bohndiek, Co-Lead, Early Detection Programme and Reader in Biomedical Physics
11:15
Keynote address: From data to evidence: using modelling to make the most out of early detection research studies. Professor Ruth Etzioni, Affiliate Professor of Biostatistics and Health Services, University of Washington, US and Member of Biostatistics Programme, Fred Hutchison Cancer Research Centre, US Chair: Professor Stephen Morris, RAND Professor of Health Economics, Department of Public Health and Primary Care
12:00
CONFIDENTIAL: BEST3 Trial outcome presentation Professor Rebecca Fitzgerald, Co-Lead, Early Detection Programme and Professor of Cancer Prevention Chair: Dr Harpal Kumar, Head, Johnson & Johnson Innovation, EMEA
12:30
Lightning talks from poster presenters Alexander Jung, European Bioinformatics Institute Annalise Katz-Summercorn, MRC Cancer Unit Fraser Millar, University of Edinburgh Helena Rannikmae, Department of Biochemistry Dale Waterhouse, Department of Physics Sarah Hickman, Department of Radiology Chair: Dr Jamie Blundell, UKRI Future Leaders Fellow and Group Leader in the CRUK Cambridge Centre Early Detection Programme
Annual Symposium Programme
11:00
Welcome & Announcement of Pump Priming Award winners Dr Sarah Bohndiek, Co-Lead, Early Detection Programme and Reader in Biomedical Physics
11:15
Keynote address: From data to evidence: using modelling to make the most out of early detection research studies. Professor Ruth Etzioni, Affiliate Professor of Biostatistics and Health Services, University of Washington, US and Member of Biostatistics Programme, Fred Hutchison Cancer Research Centre, US Chair: Professor Stephen Morris, RAND Professor of Health Economics, Department of Public Health and Primary Care
12:00
CONFIDENTIAL: BEST3 Trial outcome presentation Professor Rebecca Fitzgerald, Co-Lead, Early Detection Programme and Professor of Cancer Prevention Chair: Dr Harpal Kumar, Head, Johnson & Johnson Innovation, EMEA
12:30
Lightning talks from poster presenters Alexander Jung, European Bioinformatics Institute Annalise Katz-Summercorn, MRC Cancer Unit Fraser Millar, University of Edinburgh Helena Rannikmae, Department of Biochemistry Dale Waterhouse, Department of Physics Sarah Hickman, Department of Radiology Chair: Dr Jamie Blundell, UKRI Future Leaders Fellow and Group Leader in the CRUK Cambridge Centre Early Detection Programme
13:00 Poster session and networking lunch
14:15
Keynote address: The repetoire of mutational signatures in human cancer and pre-cancer Professor Ludmil Alexandrov, Assistant Professor in Cellular and Molecular Medicine at the University of California San Diego Chair: Professor Sir Mike Stratton, Director of the Wellcome Sanger Institute and Chief Executive Officer of the Wellcome Genome Campus
15:00
Short talks from abstracts submitted Mr Joe Dennis, Centre for Cancer Genetics Identifying rare copy number variants using genome-wide array data Dr Juliet Usher-Smith, Public Health & Primary Care A health economic analysis evaluating the potential for risk stratification to improve efficiency and equity in colorectal cancer screening Chair: Mr Grant Stewart, University Lecturer and Honorary Consultant Urological Surgeon
15:30
Future vision for Early Detection from health tech investors Chair: Dr Andy Richards, Biotechnology entrepreneur and investor
16:15
Concluding remarks & announcement of poster winner Professor Richard Gilbertson, Director of the CRUK Cambridge Centre
16:30 Finish
Speaker biographies 11:00 - Welcome + announcement of Pump Priming Awards
Dr Sarah Bohndiek Sarah is Co-Lead of the CRUK Cambridge Centre Early Detection Programme. She is a Reader in Biomedical Physics and Group Leader of a lab that operates jointly between the Department of Physics and the Cancer Research UK Cambridge Institute. Sarah’s lab develops
novel imaging technologies for early cancer detection and to better understand cancer therapy response. 11:15 - Keynote address: From data to evidence: using modelling to make the most out of early detection research studies
Dr Ruth Etzioni Dr Etzioni is a Distinguished Scientist in the Center for Early Detection Advanced Research at the Knight Cancer Institute and a Full Member in the Public Health Sciences Division at Fred Hutch Cancer Research Center. She grew up in South Africa and received her PhD in Statistics from
Carnegie Mellon University. Her research uses statistical and simulation models to address evidence gaps that inevitably arise in medical decision making and cancer policy development. She is a member of three US panels on early detection in cancer including the American Cancer Society’s Screening Guideline Development Panel. She is a fellow of the American Statistical Association and immediate past chair of its Health Policy Statistics Section.
Professor Stephen Morris (session chair) Steve Morris is the RAND Professor of Health Services Research at the University of Cambridge. He leads the Cambridge Research Methods Hub (CRMH), is co-Director of the Cambridge Centre for Health Services Research (CCHSR), and is Deputy Director of the Primary Care Unit
(PCU). He is an experienced health economist, having completed his PhD in economics in 2002. He worked previously at University College London (where he was Professor of Health Economics), Brunel University London (Reader), Imperial College London (Senior lecturer) and City University London (Lecturer). He was elected to his current position with effect from 1 June 2019. 12:00 - BEST3 Trial outcome presentation note: this talk is confidential
Professor Rebecca Fitzgerald Rebecca is Professor of Cancer Prevention at the University of Cambridge and Co-Lead of the Early Detection Programme at the CRUK Cambridge Centre. She is currently also interim director of the MRC Cancer Unit. Rebecca combines her work as a clinical gastroenterolo-
gist at Addenbrooke’s with running a research programme at the MRC Cancer Unit. She has devoted her career to understanding the earliest steps of cancer development and how we can use this knowledge to develop clinical tools to diagnose oesophageal and gastric cancer early. Rebecca is keen to accelerate the development and adoption of new methods for the early detection of cancer.
Sir Harpal Kumar (session chair) Harpal is the Head of Johnson & Johnson Innovation EMEA, based in the London Innovation Center. He oversees a portfolio of investments and collaborations across the region’s innovation community. Before joining Johnson & Johnson Innovation, Harpal spent 15 years
with Cancer Research UK and served as the organisation’s CEO. Prior to this he worked with McKinsey & Co, was CEO of The Papworth Trust and was founding CEO of Nexan Group. Harpal gained a Masters in Chemical Engineering from the University of Cambridge, and an MBA as a Baker Scholar from Harvard Business School. He has been awarded multiple Honorary Doctorates and Fellowships and he holds an Honorary Chair in Cancer Science. In 2016, he was knighted by Her Majesty Queen Elizabeth II for services to cancer research.
12:30 - Lightning talks from poster presenters - in speaking order Alexander Jung, European Bioinformatics Institute (EBI) ¹ Population-scale cancer risk prediction from disease histories Annalise Katz-Summercorn, MRC Cancer Unit¹ Multi-omic characterisation of Barrett’s oesophagus reveals a molecular continuum in the progression to oesophageal adenocarcinoma Fraser Millar, University of Edinburgh The senescence regulator Toll-like receptor 2 has a tumour suppressor function in early stage non-small cell lung cancer Helena Rannikmae, Department of Biochemistry¹ APC inactivation in early intestinal tumorigenesis leads to compromised cellular organisation Dale Waterhouse, Department of Physics¹ Multispectral endoscopy for early detection of dysplasia in Barrett’s oesophagus (MuSE): a first-in-human pilot study Sarah Hickman, Department of Radiology ¹ Mammographic case conspicuity, a comparison between a radiologist’s assessment and a Masking Index ¹ University of Cambridge
Dr Jamie Blundell (session chair) Jamie is a UKRI Future Leaders Fellow and group leader in the CRUK Cambridge Centre Early Detection Programme. He trained as a theoretical physicist at Cambridge and then as a quantitative biologist at Stanford. In 2017 he joined the Early Detection Programme as a group leader.
His lab studies the somatic evolution that occurs in healthy tissues as we age and how this evolution is altered at the earliest stages of cancer. Focusing predominantly on blood cancers, Jamie’s lab develops and
applies novel ultra-sensitive sequencing technologies to large collections of longitudinal blood samples and then applies quantitative principles from evolutionary theory to develop personalised “forecasts” of future cancer risk and identify those most in need of intervention. 13:00 - Poster session and networking lunch Wendy Alderton, Department of Oncology ¹ ACED Clinic Cambridge - delivering first-in-human testing for the International Alliance for Cancer Early Detection (ACED) Adelyne Chan, CRUK Cambridge Institute ¹ Development of oncogenic RAS ‘predictive reporter’ system for investigating dose dependency in Oncogene-Induced senescence Jinqi Fu, Department of Oncology ¹ Development of a high-resolution in-situ DNA barcoding system Garth Funston, Department of Public Health and Primary Care ¹ The predictive value of CA125 for ovarian and non-ovarian cancer in primary care: a population-based cohort study Michele Giunta, Biosignatures, Newcastle Optimising large scale clinical biomarker discovery and validation from the modified proteome Laragh Harvey-Kelly, Department of Public Health and Primary Care ¹ Kidney cancer screening: public attitudes and intentions Sarah Hickman, Department of Radiology ¹ Mammographic case conspicuity, a comparison between a radiologist’s assessment and a Masking Index Alexander Jung, European Bioinformatics Institute ¹ Population-scale cancer risk prediction from disease histories
Annalise Katz-Summercorn, MRC Cancer Unit ¹ Multi-omic characterisation of Barrett’s oesophagus reveals a molecular continuum in the progression to oesophageal adenocarcinoma Sarah Killcoyne, MRC Cancer Unit ¹ Classifying the risk of progression to Oesophageal Adenocarcinoma using whole-genome copy number in Barrett’s Oesophagus Ermira Lleshi, Department of Oncology ¹ Developing a low-cost platform for circulating methylated tumour DNA detection in blood. Fraser Millar, University of Edinburgh The senescence regulator Toll-like receptor 2 has a tumour suppressor function in early stage non-small-cell lung cancer Hui-Ling Ou, Department of Oncology ¹ Impact of senescence on tumor microenvironment Helena Rannikmae, Department of Biochemistry ¹ APC inactivation in early intestinal tumorigenesis leads to compromised cellular organisation Sabrina Rossi, Department of Oncology ¹ Characterising DNA methylation patterns in tissue and circulating tumour DNA of patients with renal cancer to enable earlier detection Manuela Urbischek, Department of Biochemistry ¹ A novel functional variant of TCF7L2 stratifies a unique colon cancer subset Aditi Vedi, Wellcome - MRC Cambridge Stem Cell Institute ¹ Functional role of DNMT3A pre-leukemic mutations in human haematopoietic stem and progenitor cells
Dale Waterhouse, Department of Physics ¹ Multispectral endoscopy for early detection of dysplasia in Barrett’s oesophagus (MuSE): a first-in-human pilot study Caroline Watson, Department of Oncology ¹ The evolutionary dynamics and natural history of Acute Myeloid Leukaemia (AML) Zhenguang Zhang, Department of Oncology ¹ Cell reprogramming reduces lung tumour growth ¹ University of Cambridge 14:15 - Keynote address: The repetoire of mutational signatures in human cancer and pre-cancer
Assistant Professor Ludmil Alexandrov Ludmil Alexandrov is an Assistant Professor of Cellular and Molecular Medicine at the University of California, San Diego. He received his Ph.D. in Cancer Genetics from the Wellcome Sanger Institute and the University of Cambridge. Ludmil’s research has been focused on
understanding the mutational processes in cancer. In 2013, he developed the first comprehensive map of the mutational signatures in human cancer. More recently, Ludmil mapped the signatures of clock-like mutational processes operative in normal somatic cells, demonstrated that mutational signatures have the potential to be used for targeted cancer therapy, identified the mutational signatures associated with tobacco smoking, and provided the most detailed map of mutational signatures in human cancer.
Professor Sir Mike Stratton (session chair) Mike studied medicine at the University of Oxford and Guy’s Hospital, and trained as a histopathologist before embarking on a PhD in the molecular biology of cancer at the Institute of Cancer Research in 1989. Mike took up a Faculty appointment at the Institute of Cancer Research
where he led the mapping and subsequent identification of BRCA2, the breast cancer susceptibility gene. Mike went on to uncover further breast cancer genes, broadening understanding of the genetic basis of breast cancer susceptibility and cancer predisposition genes more widely. In 1999 Mike proposed the Cancer Genome Project and in 2000 joined the Sanger Institute’s Faculty. In 2010 he became Director of the Sanger Institute and 2012 Chief Executive Officer of the Wellcome Genome Campus. 15:00 - Short talks from abstracts submitted
Mr Joe Dennis Identifying rare copy number variants using genome-wide array data Joe works as a bioinformatician at the Centre for Cancer Genetic Epidemiology, researching the genetics of breast, ovarian, prostate and endometrial cancer. He has worked
mainly on two large projects, iCOGS and Oncoarray, which used geno-typing chips customised to detect cancer-associated variants. The Breast Cancer Association Consortium (BCAC) has genotyped more than 200,000 samples with these arrays and discovered more than 100 associated loci. He is close to completing a PhD, supervised by Professor Doug Easton, that focuses on detecting rare deletions and duplications in the genome and assessing their contribution to breast cancer risk.
Dr Juliet Usher-Smith A health economic analysis evaluating the potential for risk stratification to improve efficiency and equity in colorectal cancer screening Dr Juliet Usher-Smith is a GP, Clinical Senior Research Associate and Cancer Research UK Prevention Fellow in
the Primary Care Unit in the Department of Public Health and Primary Care. Her research focuses on the prevention of cancer through behav-iour change and screening and she has a particular interest in the implementation of risk prediction models within screening programmes.
Mr Grant Stewart (session chair) Mr Stewart is an academic surgeon at the University of Cambridge, where he is Lead for Surgical Oncology, with a focus on developing and promoting surgery related clinical trials and translational research. As a University Lecturer in Urological Surgery, Grant has a specific interest
in optimising management of patients with initially localised renal cancer, an area of great need within the disease. He is particularly interested in the concepts of early detection and screening for kidney cancer as well as peri-surgical systemic therapy to optimise survival. Mr Stewart has developed a range of interlinked clinical trials and translational research which are all underpinned by clinical excellence in managing renal cancer at Addenbrooke’s Hospital, Cambridge. Grant also coordinates the Cambridge Renal Cancer Collaboration (CamRenCan), a group of over 40 clinicians, translational researchers and basic scientists across the Cambridge Biomedical Campus with a shared interest in renal cancer research.
15:30 - Future vision for Early Detection from health tech investors
Vishal Gulati, Draper Esprit Dr Vishal Gulati is one of the most active investors and promoters of data driven healthcare in Europe with an active portfolio of about 20 companies. These companies represent a wide range of technology platforms and applications. From digital therapeutics (e.g. Closed Loop
Medicine, Ieso Digitial Health, Clue) to machine learning and AI (Kheiron, AI VIVO, Turbine), omics/synbio (Zoe, Evonetix) they have one theme in common, they derive their strategic value and competitive advantage from data.
Dr Jack Kreindler, Mosaic Ventures Dr. Jack Kreindler is a physician, physiologist and serial health tech entrepreneur. During his practice in NHS emergency medicine from 1999 to 2006 Jack and his tech incubator, Blueorange, built a series of ventures and the core technologies for VieLife (Cigna), DictateIT, VisualDNA
and GenieDB. In 2007 Jack founded Center for Health and Human Performance (CHHP) in London’s Harley Street. CHHP works with complex cancer patients and researches the role of cardiometabolic fitness on the prevention of, and outcomes in hard to treat cancers. Jack also lectures internationally on the future of medicine, advises Havas Health and is a guest expert presenter for CNBC, Sky Sport, BT Sport and the BBC.
Rebecca Todd, Longwall Ventures Rebecca began venture investing in 2006 while at Oxford Capital, where she took responsibility for the Oxford Gateway Funds’ investments into healthcare and life science companies, and went on to become Director, Healthcare Ventures at Imperial Innovations (now
Touchstone Innovations). Her earlier career was as a marketing consultant to pharmaceutical and life science technology companies. Rebecca has a PhD in Genetics from Nottingham University and an MBA
from Oxford University. She joined Longwall Ventures after a couple of years sabbatical break spent exploring South America in a VW camper van and focuses predominantly on medical technology opportunities.
Dr Andy Richards CBE (session chair) Andy is an entrepreneur and investor with an established track record in founding and scaling up innovative biotech and healthtech companies in the UK. He is Chairman of Arecor, Congenica, Abcodia, Closed Loop Medicine and The Babraham Research Campus and is a Director of
Silence Therapeutics plc, Ieso Digital Health Ltd, and Owlstone Medical. He is an advisor to several investment funds including Cambridge Innovation Capital and the UCL Technology Fund and was, until recently, a director of Cambridge University Hospitals NHS Foundation Trust. Andy is a Member of Cancer Research UK and has been a director of Cancer Research Technology since 2003, he is also on the investment committee of the Seed Fund. 16:15 - Concluding Remarks and announcement of poster winner
Professor Richard Gilbertson Richard Gilbertson trained as a paediatric oncologist in the UK before moving in 2000 to St. Jude Children’s Research Hospital, USA where he served as Scientific and Comprehensive Cancer Center Director, Executive Vice President and Lillian R. Cannon Endowed Chair. In August
2015, he moved back home to England where he chairs the Department of Oncology and directs the CRUK Cambridge Centre at Cambridge University. His laboratory research is focused on understanding the link between normal development and the origins of cancer, particularly brain tumours.
